By Fineline Cube 
Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based LaunXP Biomedical Co., Ltd. for vebreltinib in combination with EGFR inhibitors for the treatment of non-small cell lung cancer (NSCLC) in Asia, excluding Mainland China, Hong Kong, and Macau. This collaboration grants LaunXP exclusive rights to develop and commercialize the therapy in the specified regions.
Financial Terms and Responsibilities
Under the agreement, Apollomics will receive a $10 million upfront payment and is eligible for up to $50 million in clinical development and regulatory milestone payments, along with royalties on future net sales. LaunXP will lead the development of the vebreltinib-EGFR inhibitor combination therapy in the region.
Vebreltinib: Mechanism and Approval Status
Vebreltinib is a potent, orally bioavailable, and highly selective c-MET inhibitor that targets the HGF/c-MET pathway, which plays a critical role in tumor growth, proliferation, and resistance to targeted therapies like osimertinib. The drug has received conditional approval from China’s National Medical Products Administration (NMPA) and is under global clinical investigation, though it remains unapproved in other regions.
Clinical Efficacy and Data Highlights
Vebreltinib has demonstrated significant efficacy in both treatment-naïve and previously treated NSCLC patients, with objective response rates (ORR) of 66.7% and 61.1%, respectively. The median duration of response (DOR) and progression-free survival (PFS) also showed promising results, with DOR of 17.3 months and PFS of 13.8 months in treatment-naïve patients, and DOR of 16.7 months and PFS of 7.4 months in previously treated patients. Notably, vebreltinib’s efficacy is not affected by co-occurring MET amplification, showing high ORR even in patients without MET amplification.-Fineline Info & Tech